Life Sciences

  • July 16, 2026

    Diagnostics Co. Labcorp Settles FCA Claims For $14.5M

    Diagnostics testing company Labcorp will pay $14.5 million to settle False Claims Act allegations that it submitted unnecessary Medicare claims for urine drug tests, the Massachusetts U.S. attorney's office announced.

  • July 15, 2026

    Albertsons Slow To Review Wash. Opioid Sales, Judge Told

    Albertsons conducted few reviews of opioid dispensing by its Washington pharmacies for years after establishing a controlled substances compliance team, according to testimony played on Day 3 of a bench trial in the state's lawsuit accusing the company and its Safeway subsidiary of exacerbating Washington's opioid epidemic.

  • July 15, 2026

    Circuit-By-Circuit Guide To The US Supreme Court's Term

    Federal appeals courts had wide-ranging successes and struggles during the U.S. Supreme Court's recently completed term: One had its best showing in years following its worst showing in years; one felt déjà vu after recently starting to find favor with the justices; and one saw its reputation for independence occupy a rare role in the Supreme Court spotlight.

  • July 15, 2026

    Unilever Tangled In Litigation Again Over TRESemme

    Unilever's personal care unit was hit with a products liability lawsuit in New Jersey federal court Tuesday by customers who say the company's TRESemme shampoo products caused them to suffer scalp irritation, bald spots or their hair to fall out in clumps.

  • July 15, 2026

    Acorda Can't Add $66M To Award In Ampyra Royalty Fight

    The Second Circuit on Wednesday refused to alter an arbitral award issued to Acorda Therapeutics to include nearly $66 million beyond the $16.6 million it won in a multiple sclerosis drug dispute, saying the company "slept on its rights" and couldn't change the result now.

  • July 15, 2026

    Bristol Myers Sues Generics Cos. Over Planned Cardiac Drug

    Bristol Myers Squibb and MyoKardia have filed patent infringement suits in Delaware against a variety of pharmaceutical companies, including MSN Laboratories and Dr. Reddy's Laboratories, targeting their planned generic versions of the cardiac drug Camzyos.

  • July 15, 2026

    Braveheart Bio, Attovia Join Growing Pipeline Of Biotech IPOs

    Two venture-backed biotechnology firms filed plans for initial public offerings this week, both with plans to raise around $100 million for their public debut.

  • July 15, 2026

    Polsinelli, Doctor Seek Toss Of 'Bad Faith' Patent Claims

    Polsinelli PC and a doctor who has been a client of the law firm have asked Mississippi and Tennessee federal courts to throw out Zavation Medical Products LLC and Choice Spine LLC's allegations that the firm and its client violated respective state laws by bringing "bad faith" patent infringement claims, saying the statutes the medical device makers rely on can't be brought by distributors or manufacturers.

  • July 15, 2026

    What To Watch In Massachusetts In The 2nd Half Of 2026

    As midsummer approaches, Massachusetts attorneys are focused on much more than just the Red Sox winning streak and the fallout from the Jaylen Brown trade; from a headline-grabbing federal prosecution to the midterm elections to cases that could shape the state's noncompete laws, practitioners have plenty on their radar in the latter half of the year.

  • July 15, 2026

    Squires Grants 10 PTAB Petitions, Denies 14 In Newest Order

    U.S. Patent and Trademark Office Director John Squires turned away 14 Patent Trial and Appeal Board petitions on Tuesday, while instituting another 10.

  • July 15, 2026

    9th Circ. Won't Revive Flea, Tick Meds Suit Against Bayer

    A Ninth Circuit panel gave short shrift to Tevra Brand LLC's bid to revive an antitrust suit alleging Bayer HealthCare LLC used exclusive contracts to lock up the market for a flea and tick treatment for dogs and cats, preserving Bayer's jury win.

  • July 15, 2026

    Covidien Hid Mesh Risk From Doctors, Bellwether Jury Told

    A Massachusetts federal jury in the first bellwether trial over Covidien LP's hernia mesh products was told Wednesday that doctors were not warned about how quickly a safety feature could dissolve after the mesh is implanted in a patient's body.

  • July 15, 2026

    Glenmark Reaches $29M Deal In Generics Price-Fixing Case

    Glenmark Pharmaceuticals Inc. and 48 states and territories have reached a $29.6 million settlement resolving allegations the company fixed prices in the generic pharmaceuticals market.

  • July 15, 2026

    WilmerHale Adds Drug Pricing Regulatory Expert In Denver

    WilmerHale added an attorney to its Denver office with experience advising pharmaceutical manufacturers and other life sciences clients on drug pricing regulatory issues, continuing a string of new hires with expertise in the industry.

  • July 14, 2026

    Albertsons Probed On Pharmacy Compliance Staffing At Trial

    Two former Albertsons pharmacy compliance executives testified in video depositions played Tuesday before a Washington judge considering whether Albertsons failed to prevent the diversion of opioids in the state, acknowledging the nationwide compliance team consisted of just six staffers between 2015 and 2020 despite heightened scrutiny amid the opioid epidemic.

  • July 14, 2026

    Sanofi Says Pfizer, Moderna COVID Jabs Infringe MRNA Tech

    Sanofi's pharmaceutical and therapeutics subsidiaries say the COVID-19 vaccines that have netted Pfizer and Moderna billions of dollars infringe their patents covering mRNA technology, according to a pair of lawsuits filed Tuesday in New Jersey federal court.

  • July 14, 2026

    Patent Eligibility Bill Divides Senators Over Health Costs

    Several U.S. senators expressed strong support at a hearing Tuesday for a bill aimed at expanding which inventions are eligible for patents, while others appeared to have reservations about the potential effect of the proposed changes on healthcare costs.

  • July 14, 2026

    Bayer Defends Fees For Seed Tech With Expired Patents

    Bayer asked a Missouri federal judge to dismiss a sweeping antitrust proposed class action, arguing that the independent seed company suing it, in a complaint that also includes breach of contract allegations, is contesting perfectly legal licensing fees charged for corn technology, even after the last patents expired.

  • July 14, 2026

    Judge Says Vanda-FDA Appointments Fight Likely Ripe

    A D.C. federal judge said he likely had jurisdiction to hear Vanda Pharmaceuticals' latest challenge to the Food and Drug Administration's structure for reviewing new drug applications, but wondered if a recent U.S. Supreme Court decision might doom the company's challenge on the merits.

  • July 14, 2026

    Medical Device Co. Settles FCA Claims

    A company that sells compression devices to reduce swelling in patients with certain medical conditions will pay $551,000 to settle allegations that it obtained Medicare reimbursement with falsified medical records, the U.S. attorney's office in Massachusetts announced Tuesday.

  • July 14, 2026

    CVS Caremark Settles Out Of FTC Suit Over Insulin Pricing

    The Federal Trade Commission reached a settlement on Tuesday with CVS Caremark that includes a number of changes to its business practices, the second deal in a case accusing the country's largest pharmacy benefit managers of inflating insulin prices through unfair rebate schemes.

  • July 14, 2026

    Google Is Wrong, 'Settled Expectations' Is Legal, Justices Told

    Software company VirtaMove has argued that the U.S. Supreme Court should ignore Google's challenge to the U.S. Patent and Trademark Office's policy of using the age of patents as a reason to not review them, saying Google's fight is based on a false foundation.

  • July 14, 2026

    Cayman Judge Orders VC Apple Tree's Management Removed

    A Cayman Islands judge has appointed independent officers to direct Apple Tree Life Sciences Inc., handing a win to a fund tied to a longtime Apple Tree investor that has sought to oust the biotechnology investment company's management as part of a protracted feud.

  • July 14, 2026

    Gov't Shouldn't Face Vax Suit Targeting Moderna, Group Says

    Conservative advocacy organization Eagle Forum Education & Legal Defense Fund on Tuesday urged the Federal Circuit to reject a proposal to shift a multibillion-dollar patent infringement case over the COVID-19 vaccine that is targeting Moderna to the federal government, saying doing so would reduce the crucial economic incentives that power innovation in the pharmaceutical industry.

  • July 14, 2026

    Top Enviro Policy Developments From The First Half Of 2026

    The first half of 2026 saw the repeal of a key rule underlying federal climate regulation, the rollback of pollution limits on industrial chemicals like ethylene oxide, and a blanket exemption from species protections for Gulf oil drillers. Here, Law360 takes a look at the top five developments in environmental policy and regulation so far this year.

Expert Analysis

  • Series

    Law School's Missed Lessons: The Human Element

    Author Photo

    Law school teaches you to quickly apply intellect and logic when handling a legal issue, but every fact pattern also involves a person, making the ability to balance expertise with empathy critical to the growth of relationships with clients, colleagues and adversaries, says Rachel Adcox at Adcox Strategies.

  • Avoid The Unexpected When Drafting License Agreements

    Author Photo

    The Delaware Court of Chancery's recent decision in Commave v. Zevrain raises several practice points for attorneys drafting commercial contracts, underscoring the importance of considering anti-assignment provisions, specific exclusions and potential carveouts when drafting license agreements or other commercial contracts, say attorneys at Hogan Lovells.

  • CMS Healthcare Enforcement Initiatives May Cause Disruption

    Author Photo

    The Centers for Medicare & Medicaid Services' recently announced enforcement actions against healthcare fraud mark a significant escalation, and CMS' prior approach in the hospice sector suggests that even compliant providers and suppliers should brace for impact, say attorneys at Morgan Lewis.

  • The Benefits Of Choosing A Niche Practice In The AI Age

    Author Photo

    As artificial intelligence becomes increasingly accessible, lawyers with a niche practice may stand out as clients seek specialized judgment that automation cannot replicate, but it is important to choose a niche that is durable, engaging and a good personal fit, says Daniel Borneman at Lowenstein Sandler.

  • How PBMs Can Adapt To Plan Sponsors' Disclosure Demands

    Author Photo

    As federal reforms, growing state regulation and litigation threats push plan sponsors to expect visibility into revenue streams, pharmacy benefit managers should leverage transparency strategically, including by simplifying how they get paid, offering clients audit-ready data and co-designing contracts that are easy for fiduciaries to explain and defend, says Kristie Blase at Frazer + Blase.

  • What New Animal Welfare Enforcement Push Means For Cos.

    Author Photo

    The Trump administration's recently announced multiagency focus on violations of the Animal Welfare Act and related laws will likely lead to broader enforcement actions across industries, heightened scrutiny of compliance standards and a need for businesses to adopt effective risk management practices, says Shennie Patel at Crowell & Moring.

  • How To Engage With Gov't's Direct-To-Consumer Drug Policy

    Author Photo

    The U.S. Department of Health and Human Services' recent request for industry input on manufacturers' direct-to-consumer drug sales reflects the government's caution in this arena, and allows stakeholders a rare opportunity to help shape policy, says Mary Kohler at Kohler Health Law.

  • Series

    Podcasting Makes Me A Better Lawyer

    Author Photo

    Podcasting has changed how I ask questions and connect with people, sharpening my ability to listen without interrupting or prejudging, and bringing me closer to what law is meant to be: a human profession grounded in understanding, judgment and trust, says Donna DiMaggio Berger at Becker.

  • Patent Eligibility Bulletin: Steps To Consider As USPTO Shifts

    Author Photo

    Recent memoranda from the U.S. Patent and Trademark Office, along with some of the first patents issued under Director John Squires, indicate a recalibration of the subject matter eligibility landscape, signaling a renewed emphasis on concrete technological improvements and a potentially pro-AI stance, say attorneys at Banner Witcoff.

  • Tax Court Ruling Signals Cross-Border Loan Scrutiny

    Author Photo

    The U.S. Tax Court’s recent decision in Aventis v. Commissioner compounds ongoing regulatory focus on debt originations and should prompt practitioners to assess their existing cross-border lending structures for potential exposure to U.S. federal income tax, say attorneys at Eversheds.

  • Lessons From Justices' Split On Major Questions Doctrine

    Author Photo

    The justices' varied opinions in Learning Resources v. Trump, which held the International Emergency Economy Powers Act did not confer the power to impose tariffs, offer a meaningful window into the U.S. Supreme Court's perspective on the major questions doctrine that will likely shape lower courts' approach to executive action challenges, say attorneys at Venable.

  • Drug Wholesaler's DPA Shows Imperfect Efforts Still Count

    Author Photo

    Atlantic Biologicals’ recent deferred prosecution agreement with federal prosecutors for allegedly distributing controlled substances to pill mill pharmacies demonstrates that even subpar cooperation, when combined with genuine remediation and strategic advocacy, can yield outcomes that protect a company's long-term interests, says Jonathan Porter at Husch Blackwell.

  • Key Takeaways As HRSA Aims To Revive 340B Rebate Pilot

    Author Photo

    The U.S. Department of Health and Human Services' recent request for feedback on the 340B Rebate Model Pilot Program demonstrates that it intends to correct the model's procedural defects, which is positive news for participating manufacturers, but a setback for covered entities, say attorneys at Manatt.

  • When MDLs Drag, State Courts Can Speed Mass Tort Results

    Author Photo

    Understanding the structural dynamics that can delay resolution in multidistrict litigation is essential to understanding why a state court strategy is sometimes not merely attractive, but necessary for plaintiffs seeking timely and just outcomes, say attorneys at DiCello Levitt.

  • Leveraging MDLs And State Courts In Mass Tort Strategy

    Author Photo

    Multidistrict litigation's quiet drift from a pretrial coordination device to a de facto national court for mass torts poses a strategic question for plaintiffs counsel — whether an MDL will yield timely trials, meaningful accountability and fair value for clients, or whether a state court strategy will be more effective, say attorneys at DiCello Levitt.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.